Cart
sales@molnova.com
HA-155
CAS No. 1229652-22-5
HA-155( Autotaxin Inhibitor IV )
Catalog No. M23406 CAS No. 1229652-22-5
HA155 is a boronic acid-based compound, inhibiting ATX with IC50 of 5.7 nM by selectively binding to its catalytic threonine.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 56 | In Stock |
|
| 5MG | 119 | In Stock |
|
| 10MG | 213 | In Stock |
|
| 25MG | 511 | In Stock |
|
| 50MG | 644 | In Stock |
|
| 100MG | 786 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHA-155
-
NoteResearch use only, not for human use.
-
Brief DescriptionHA155 is a boronic acid-based compound, inhibiting ATX with IC50 of 5.7 nM by selectively binding to its catalytic threonine.
-
DescriptionHA155 is a boronic acid-based compound, inhibiting ATX with IC50 of 5.7 nM by selectively binding to its catalytic threonine.
-
In Vitro——
-
In Vivo——
-
SynonymsAutotaxin Inhibitor IV
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorATX (autotaxin)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1229652-22-5
-
Formula Weight463.29
-
Molecular FormulaC24H19BFNO5S
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESB(C1=CC=C(C=C1)COC2=CC=C(C=C2)/C=C\3/C(=O)N(C(=O)S3)CC4=CC=C(C=C4)F)(O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Albers H M H G , Hendrickx L J D , Van Tol R J P , et al. Structure-Based Design of Novel Boronic Acid-Based Inhibitors of Autotaxin[J]. Journal of Medicinal Chemistry, 2011, 54(13):4619-26.
molnova catalog
related products
-
RPL-554
RPL-554 (LS-193855, RPL554)?is a potent, orally available, dual PDE3/PDE4 inhibitor with IC50 of 0.4 nM and 1479 nM, respectively.
-
EMD57439
EMD57439 is a selective PDE-III inhibitor, showing no significant increase in c-AMP concentration and producing little change in Ca(50).
-
Mirodenafil
Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.The pharmacoki-netics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil (50 or 100 mg), obviously improved erectile function and was well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities.
